NASDAQ:NOVN
Delisted
Novan, Inc. Stock News
$0.0941
+0 (+0%)
At Close: Nov 20, 2023
Novartis plans to petition the U.S. Supreme Court to uphold validity of the Gilenya® (fingolimod) dosing regimen patent
05:00am, Wednesday, 21'st Sep 2022 GlobeNewswire Inc.
Ad hoc announcement pursuant to Art. 53 LR
Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial
05:15am, Monday, 19'th Sep 2022 GlobeNewswire Inc.
Basel, September 19, 2022 – Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announces further progress on its biosimilar pipeline, with the release of positive result
Novartis says authorities investigating a patent assertion
06:34am, Thursday, 15'th Sep 2022 MarketWatch
The probe into Novartis's assertion of a patent in the broader field of dermatology treatments doesn't imply wrongdoing or financial impact, the company said.
Novartis statement regarding competition authority investigation into assertion of a patent
05:30am, Thursday, 15'th Sep 2022 GlobeNewswire Inc.
Basel, September 15, 2022 — Novartis today confirms that it has been contacted by the Swiss Competition Commission (COMCO) which has initiated an investigation, in collaboration with the European Co
Novartis Cosentyx® shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal Phase III trials
06:30am, Saturday, 10'th Sep 2022 GlobeNewswire Inc.
Basel, September 10, 2022 — Novartis announced the results from two pivotal, Phase III studies (SUNSHINE and SUNRISE), in which Cosentyx® (secukinumab) demonstrated rapid and sustained relief from
Novartis Kisqali® adds one more year of survival benefit for broadest set of patients, including those with aggressive HR+/HER2- advanced breast cancer
05:15am, Friday, 09'th Sep 2022 GlobeNewswire Inc.
Basel, September 9, 2022 — Novartis today announced results from a new pooled exploratory analysis across the entire MONALEESA Phase III program, confirming nearly one year of additional overall sur
Novartis highlights depth of immunology pipeline with novel data at key upcoming international congresses
05:15am, Friday, 02'nd Sep 2022 GlobeNewswire Inc.
Basel, September 2, 2022 — Novartis today announced it will showcase data from its leading immunology portfolio and emerging pipeline at the upcoming 31st European Academy of Dermatology and Venereo
Novartis appoints Fiona Marshall, Ph.D., President of the Novartis Institutes for BioMedical Research as Jay Bradner, M.D., steps down from the Executive Committee of Novartis
05:00am, Thursday, 01'st Sep 2022 GlobeNewswire Inc.
Basel, September 1, 2022 — Novartis today announced that James (Jay) E. Bradner, M.D., will step down from the Executive Committee of Novartis (ECN), effective October 31st after seven years leading
Novartis presents new data in breast and prostate cancer at ESMO
05:15am, Tuesday, 30'th Aug 2022 GlobeNewswire Inc.
Basel, August 30, 2022 — Novartis will showcase new data from across its oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2022 with over 35 accepted abstracts from Nov
Novartis to spin off, list Sandoz business
05:53am, Thursday, 25'th Aug 2022 MarketWatch
The Swiss pharmaceutical company said Sandoz would be based in Switzerland and listed locally alongside a an American depositary receipt program in the U.S.
Novartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off
05:00am, Thursday, 25'th Aug 2022 GlobeNewswire Inc.
Ad hoc announcement pursuant to Art. 53 LR
Novartis will das Sandoz Geschäft durch eine hundertprozentige Ausgliederung als eigenständiges Unternehmen abspalten
05:00am, Thursday, 25'th Aug 2022 GlobeNewswire Inc.
Ad-hoc-Mitteilung gemäss Art. 53 KR
Is WisdomTree International High Dividend ETF (DTH) a Strong ETF Right Now?
10:20am, Wednesday, 17'th Aug 2022 Zacks Investment Research
Smart Beta ETF report for DTH
Novan, Inc. (NOVN) CEO Paula Stafford on Q2 2022 Results - Earnings Call Transcript
10:29pm, Thursday, 11'th Aug 2022
Novan, Inc. (NASDAQ:NOVN ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Paula Stafford - President, CEO & Chairwoman John Gay - CFO & Corporate Secretary John Donof
Novan to Report Second Quarter 2022 Financial Results on August 11, 2022
01:05pm, Thursday, 04'th Aug 2022 GlobeNewswire Inc.
DURHAM, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its second quarter 2022 financial results on Thursd
